Claro Advisors LLC lifted its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 10.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 26,088 shares of the company’s stock after acquiring an additional 2,509 shares during the period. Claro Advisors LLC’s holdings in Novo Nordisk A/S were worth $3,106,000 as of its most recent filing with the SEC.
A number of other institutional investors have also added to or reduced their stakes in NVO. Advisor OS LLC lifted its holdings in Novo Nordisk A/S by 0.6% during the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock worth $1,994,000 after buying an additional 82 shares in the last quarter. Cascade Financial Partners LLC lifted its stake in shares of Novo Nordisk A/S by 2.3% during the second quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock valued at $543,000 after acquiring an additional 84 shares during the period. Novare Capital Management LLC boosted its holdings in Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after acquiring an additional 85 shares during the last quarter. AA Financial Advisors LLC increased its position in Novo Nordisk A/S by 3.2% in the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after purchasing an additional 86 shares during the period. Finally, Steel Grove Capital Advisors LLC raised its holdings in Novo Nordisk A/S by 2.3% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock worth $541,000 after purchasing an additional 86 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.
Novo Nordisk A/S Trading Down 3.4 %
NVO opened at $101.74 on Friday. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The firm has a market cap of $456.56 billion, a PE ratio of 32.93, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm’s fifty day moving average is $118.58 and its two-hundred day moving average is $129.59.
Analyst Ratings Changes
View Our Latest Stock Analysis on Novo Nordisk A/S
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
- Five stocks we like better than Novo Nordisk A/S
- What is a Special Dividend?
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What is a Dividend King?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.